
MK-0343
CAS No. 233275-76-8
MK-0343 ( MRK-409 | MK0343 )
产品货号. M13670 CAS No. 233275-76-8
MK-0343 (MRK-409) 是一种有效的 α2/3 亚型选择性部分 GABAA 受体激动剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥3021 | 有现货 |
![]() ![]() |
50MG | ¥11664 | 有现货 |
![]() ![]() |
100MG | ¥17658 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称MK-0343
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述MK-0343 (MRK-409) 是一种有效的 α2/3 亚型选择性部分 GABAA 受体激动剂。
-
产品描述MK-0343 (MRK-409) is a potent, α2/3 subtype selective, partial GABAA receptor agonist, shows greater agonist efficacy at the α3 over α1 subtypes; readily penetrates the brain in rats and occupies the benzodiazepine site of GABA(A) receptors with an Occ(50) of 2.2 mg/kg p.o. and a corresponding plasma EC50 of 115 ng/mL; produces anxiolytic-like activity in rodent and primate unconditioned and conditioned models of anxiety.
-
体外实验——
-
体内实验MK0343 readily penetrates the brain in rats and occupies the benzodiazepine site of GABAA receptors, measured using an in vivo [3H]flumazenil binding assay, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL. Animal Model:Male Sprague-Dawley rats (approximately 250–300g) (pharmacokinetics)Dosage:1, 2 or 3?mg/kg Administration:Oral administration Result:Readily penetrated the brain in rats and occupies the benzodiazepine site of GABAA receptors, with an Occ50 of 2.2?mg/kg p.o. and a corresponding plasma EC50 of 115?ng/mL.
-
同义词MRK-409 | MK0343
-
通路Membrane Transporter/Ion Channel
-
靶点GAT
-
受体GAT
-
研究领域Other Indications
-
适应症——
化学信息
-
CAS Number233275-76-8
-
分子量397.39
-
分子式C19H17F2N7O
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 250 mg/mL (629.12 mM)
-
SMILESCN1N=CN=C1COC2=NN3C(C=C2C4CCC4)=NN=C3C5=C(F)C=CC=C5F
-
化学全称7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Atack JR, et al. J Psychopharmacol. 2011 Mar;25(3):314-28.
2. de Haas SL, et al. J Psychopharmacol. 2008 Jan;22(1):24-32.